DrugPatentWatch Database Preview
PHENTERMINE HYDROCHLORIDE Drug Profile
» See Plans and Pricing
Which patents cover Phentermine Hydrochloride, and what generic alternatives are available?
Phentermine Hydrochloride is a drug marketed by Abc Holding, Able, Aurolife Pharma Llc, Barr, Camall, Chartwell Rx, Duramed Pharms Barr, Elite Labs, Elite Labs Inc, Invagen Pharms, Ivax Pharms, Kvk Tech, Lannett, Lannett Co Inc, Nuvo Pharm, Sandoz, Sun Pharm Industries, Teva, Tg United Inc, Upsher Smith Labs, Usl Pharma, Vitarine, Watson Labs, Zydus Pharms, Actavis Elizabeth, Kvk Tech Inc, Novast Labs, Polygen Pharms, Prinston Inc, Sandoz Inc, and Sun Pharm Inds Inc. and is included in eighty-seven NDAs.
The generic ingredient in PHENTERMINE HYDROCHLORIDE is phentermine hydrochloride. There are seventeen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the phentermine hydrochloride profile page.
US ANDA Litigation and Generic Entry Outlook for Phentermine Hydrochloride
A generic version of PHENTERMINE HYDROCHLORIDE was approved as phentermine hydrochloride by ELITE LABS INC on May 30th, 1997.
Summary for PHENTERMINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 31 |
NDAs: | 87 |
Suppliers / Packagers: | 30 |
Bulk Api Vendors: | 36 |
Clinical Trials: | 40 |
Patent Applications: | 805 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PHENTERMINE HYDROCHLORIDE |
DailyMed Link: | PHENTERMINE HYDROCHLORIDE at DailyMed |

Recent Clinical Trials for PHENTERMINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Minnesota | Phase 3 |
University of Florida | Phase 3 |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 3 |
Pharmacology for PHENTERMINE HYDROCHLORIDE
Drug Class | Sympathomimetic Amine Anorectic |
Physiological Effect | Appetite Suppression Increased Sympathetic Activity |
Paragraph IV (Patent) Challenges for PHENTERMINE HYDROCHLORIDE
Tradename | Dosage | Ingredient | NDA | Submissiondate |
---|---|---|---|---|
SUPRENZA | TABLET, ORALLY DISINTEGRATING;ORAL | phentermine hydrochloride | 202088 | 2013-03-22 |
SUPRENZA | TABLET, ORALLY DISINTEGRATING;ORAL | phentermine hydrochloride | 202088 | 2012-10-19 |